Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127417681 | 12741768 | 1 | I | 20160830 | 20160914 | 20160914 | EXP | CN-ELI_LILLY_AND_COMPANY-CN201609004311 | ELI LILLY AND CO | 0.00 | Y | 0.00000 | 20160913 | OT | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127417681 | 12741768 | 1 | PS | ERBITUX | CETUXIMAB | 1 | Intravenous (not otherwise specified) | 400 MG/M2, WEEKLY (1/W) | U | U | 125084 | 400 | MG/M**2 | /wk | |||||
| 127417681 | 12741768 | 2 | SS | ERBITUX | CETUXIMAB | 1 | Intravenous (not otherwise specified) | 250 MG/M2, WEEKLY (1/W) | U | U | 125084 | 250 | MG/M**2 | /wk | |||||
| 127417681 | 12741768 | 3 | SS | FLUOROURACIL. | FLUOROURACIL | 1 | Intravenous (not otherwise specified) | 375 MG/M2, QD | U | 0 | 375 | MG/M**2 | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127417681 | 12741768 | 1 | Colorectal cancer |
| 127417681 | 12741768 | 3 | Colorectal cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127417681 | 12741768 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127417681 | 12741768 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |